Topical Minocycline Foam FXFM244

Phase 2Small molecule

VVyne Therapeutics Inc.

Topical Minocycline Foam FXFM244 is one of 39 small molecule programs targeting Rosacea. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RosaceaActive, not recruiting

ImpetigoActive, not recruiting

RosaceaPhase 2

Active, not recruiting

ImpetigoPhase 2

Active, not recruiting

Competition

Competitive Landscape

87 competitors in Rosacea

#DrugCompanyPhaseTrials

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

4 2

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

1 3

Doryx

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Otezla

Amgen

Phase 2

1 5

Daliresp

AstraZeneca

Phase 2

1 6

Elavil

AstraZeneca

Phase 2

1 7

Tofranil

Sanofi

Phase 2

1 8

Aimovig

Xifaxan

3 10

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Minocycline

NCT07462702

Clinical

Trials by Indication[1]

Acne Vulgaris1 trial

Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients

Completed·VVyne Therapeutics Inc.·Phase 2·NCT01362010·150 enrolled

Impetigo1 trial

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

Completed·VVyne Therapeutics Inc.·Phase 2·NCT01171326·32 enrolled

Rosacea1 trial

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients

Terminated·VVyne Therapeutics Inc.·Phase 2·NCT01134991·21 enrolled

Minocycline1 trial

Topical Minocycline for CARP

Not yet recruiting·MMedical University of South Carolina·Phase 1·NCT07462702·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Topical Minocycline Foam FXFM244. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Topical Minocycline Foam FXFM244 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Topical Minocycline Foam FXFM244. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vyne Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVyne Therapeutics Inc.

Topical Minocycline Foam FXFM244

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Acne Vulgaris1 trial

Impetigo1 trial

Rosacea1 trial

Minocycline1 trial

References

Drug Info

Quick Facts

Related News